CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade DiaMedica Therapeutics Inc. - DMAC CFD

1.4773
2.04%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0854
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.024874 %
Charges from borrowed part ($-0.99)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.024874%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.002651 %
Charges from borrowed part ($0.11)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.002651%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.4477
Open* 1.3882
1-Year Change* -42.87%
Day's Range* 1.3686 - 1.4872
52 wk Range 1.12-2.71
Average Volume (10 days) 23.15K
Average Volume (3 months) 743.65K
Market Cap 38.87M
P/E Ratio -100.00K
Shares Outstanding 26.46M
Revenue N/A
EPS -0.52
Dividend (Yield %) N/A
Beta 1.75
Next Earnings Date May 3, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 30, 2023 1.4477 0.0301 2.12% 1.4176 1.5262 1.3880
Mar 29, 2023 1.4382 -0.0478 -3.22% 1.4860 1.5061 1.3688
Mar 28, 2023 1.4869 -0.0281 -1.85% 1.5150 1.5947 1.4763
Mar 27, 2023 1.4573 0.0693 4.99% 1.3880 1.5068 1.3880
Mar 24, 2023 1.5261 0.1576 11.52% 1.3685 1.5261 1.3684
Mar 23, 2023 1.4380 -0.1068 -6.91% 1.5448 1.5751 1.4380
Mar 22, 2023 1.5458 -0.0479 -3.01% 1.5937 1.6633 1.5454
Mar 21, 2023 1.6729 -0.0391 -2.28% 1.7120 1.7122 1.5843
Mar 20, 2023 1.6925 -0.0382 -2.21% 1.7307 1.7314 1.6529
Mar 17, 2023 1.7316 -0.0188 -1.07% 1.7504 1.7505 1.7010
Mar 16, 2023 1.8296 0.0891 5.12% 1.7405 1.8394 1.7405
Mar 15, 2023 1.6923 -0.0383 -2.21% 1.7306 1.7416 1.6820
Mar 14, 2023 1.7805 0.0878 5.19% 1.6927 1.8297 1.6422
Mar 13, 2023 1.6922 0.1276 8.16% 1.5646 1.7221 1.5646
Mar 10, 2023 1.6531 -0.0182 -1.09% 1.6713 1.7019 1.5645
Mar 9, 2023 1.6923 0.0502 3.06% 1.6421 1.7707 1.6421
Mar 8, 2023 1.7709 0.0994 5.95% 1.6715 1.7906 1.6715
Mar 7, 2023 1.7219 0.0798 4.86% 1.6421 1.7221 1.6421
Mar 6, 2023 1.7020 -0.0188 -1.09% 1.7208 1.7612 1.6723
Mar 3, 2023 1.7316 0.0790 4.78% 1.6526 1.7514 1.6526

DiaMedica Therapeutics Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total revenue 0 0 0 0.5 0
Total Operating Expense 13.646 12.699 11.593 7.261 4.519
Selling/General/Admin. Expenses, Total 4.881 4.389 3.693 2.739 1.313
Research & Development 8.765 8.31 7.9 4.522 3.206
Depreciation / Amortization
Operating Income -13.646 -12.699 -11.593 -6.761 -4.519
Interest Income (Expense), Net Non-Operating 0 -0.039 0.009
Other, Net 0.082 0.434 0.975 1.146 0.25
Net Income Before Taxes -13.564 -12.265 -10.618 -5.654 -4.26
Net Income After Taxes -13.592 -12.292 -10.649 -5.734 -4.26
Net Income Before Extra. Items -13.592 -12.292 -10.649 -5.734 -4.26
Net Income -13.592 -12.292 -10.649 -5.734 -4.26
Income Available to Common Excl. Extra. Items -13.592 -12.292 -10.649 -5.734 -4.26
Income Available to Common Incl. Extra. Items -13.592 -12.292 -10.649 -5.734 -4.26
Diluted Net Income -13.592 -12.292 -10.649 -5.734 -4.26
Diluted Weighted Average Shares 20.7734 15.6803 11.9877 7.74352 5.93579
Diluted EPS Excluding Extraordinary Items -0.6543 -0.78391 -0.88833 -0.74049 -0.71768
Diluted Normalized EPS -0.6543 -0.78391 -0.88833 -0.74049 -0.71768
Revenue 0 0.5 0
Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021
Total revenue 0 0 0 0 0
Total Operating Expense 3.128 3.364 3.536 3.246 3.416
Selling/General/Admin. Expenses, Total 1.488 1.409 1.562 1.375 1.084
Research & Development 1.64 1.955 1.974 1.871 2.332
Operating Income -3.128 -3.364 -3.536 -3.246 -3.416
Other, Net 0.076 0.013 0.035 0.007 -0.027
Net Income Before Taxes -3.052 -3.351 -3.501 -3.239 -3.443
Net Income After Taxes -3.059 -3.358 -3.508 -3.246 -3.45
Net Income Before Extra. Items -3.059 -3.358 -3.508 -3.246 -3.45
Net Income -3.059 -3.358 -3.508 -3.246 -3.45
Income Available to Common Excl. Extra. Items -3.059 -3.358 -3.508 -3.246 -3.45
Income Available to Common Incl. Extra. Items -3.059 -3.358 -3.508 -3.246 -3.45
Diluted Net Income -3.059 -3.358 -3.508 -3.246 -3.45
Diluted Weighted Average Shares 26.4431 26.4431 26.4431 26.5021 19.0357
Diluted EPS Excluding Extraordinary Items -0.11568 -0.12699 -0.13266 -0.12248 -0.18124
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.11568 -0.12699 -0.13266 -0.12248 -0.18124
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Total Current Assets 45.439 27.921 8.836 17.972 1.494
Cash and Short Term Investments 45.112 27.507 7.878 16.823 1.353
Cash 4.707 7.409 3.883 16.823 1.353
Total Receivables, Net 0.13 0.34 0.823 0.78 0.08
Prepaid Expenses 0.084 0.064 0.047 0.369 0.061
Total Assets 45.551 28.095 9.053 18.339 1.802
Property/Plant/Equipment, Total - Net 0.112 0.174 0.217 0.096 0.037
Property/Plant/Equipment, Total - Gross 0.179 0.231 0.26
Accumulated Depreciation, Total -0.067 -0.057 -0.043
Total Current Liabilities 1.524 2.028 1.318 1.296 1.003
Accounts Payable 0.509 1.099 0.182
Accrued Expenses 1.011 0.923 1.13
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0 0.084
Total Liabilities 1.527 2.081 1.436 1.314 1.003
Total Long Term Debt 0.003 0.007 0.013 0.018 0
Other Liabilities, Total 0 0.046 0.105
Total Equity 44.024 26.014 7.617 17.025 0.799
Common Stock 0 0 0 0 0
Additional Paid-In Capital 126.576 94.925 64.232 62.993 41.033
Retained Earnings (Accumulated Deficit) -82.501 -68.909 -56.617 -45.968 -40.234
Other Equity, Total -0.051 -0.002 0.002
Total Liabilities & Shareholders’ Equity 45.551 28.095 9.053 18.339 1.802
Total Common Shares Outstanding 26.4431 18.7462 12.0069 11.9569 6.37066
Accounts Receivable - Trade, Net 0.13 0.78 0.08
Other Long Term Assets, Total 0 0.271 0.271
Payable/Accrued 1.291 0.919
Current Port. of LT Debt/Capital Leases 0.004 0.006 0.006 0.005 0
Capital Lease Obligations 0.003 0.007 0.013 0.018 0
Short Term Investments 40.405 20.098 3.995
Other Current Assets, Total 0.113 0.01 0.088
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Total Current Assets 42.111 45.439 48.537 21.629 24.195
Cash and Short Term Investments 41.047 45.112 48.097 21.295 23.401
Cash 3.032 4.707 16.219 2.228 3.329
Short Term Investments 38.015 40.405 31.878 19.067 20.072
Total Receivables, Net 0.168 0.13 0.104 0.016 0.337
Prepaid Expenses 0.793 0.084 0.336 0.318 0.457
Total Assets 42.211 45.551 48.664 21.774 24.356
Property/Plant/Equipment, Total - Net 0.1 0.112 0.127 0.145 0.161
Property/Plant/Equipment, Total - Gross 0.162 0.179 0.187 0.199 0.209
Accumulated Depreciation, Total -0.062 -0.067 -0.06 -0.054 -0.048
Total Current Liabilities 1.434 1.524 1.624 1.44 1.178
Accounts Payable 0.433 0.509 0.699 0.239 0.689
Accrued Expenses 0.995 1.011 0.921 1.196 0.483
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.006 0.004 0.004 0.005 0.006
Total Liabilities 1.443 1.527 1.628 1.456 1.211
Total Long Term Debt 0.009 0.003 0.004 0.005 0.005
Capital Lease Obligations 0.009 0.003 0.004 0.005 0.005
Other Liabilities, Total 0 0 0.011 0.028
Total Equity 40.768 44.024 47.036 20.318 23.145
Common Stock 0 0 0 0 0
Additional Paid-In Capital 126.884 126.576 126.296 96.126 95.68
Retained Earnings (Accumulated Deficit) -86.009 -82.501 -79.255 -75.805 -72.531
Other Equity, Total -0.107 -0.051 -0.005 -0.003 -0.004
Total Liabilities & Shareholders’ Equity 42.211 45.551 48.664 21.774 24.356
Total Common Shares Outstanding 26.4431 26.4431 26.4392 18.7862 18.7862
Accounts Receivable - Trade, Net 0.166 0.13
Other Current Assets, Total 0.103 0.113
  • Annual
  • Quarterly
2021 2020 2019 2018 2017
Net income/Starting Line -13.592 -12.292 -10.649 -5.734 -4.26
Cash From Operating Activities -12.252 -9.185 -9.102 -5.696 -3.9
Cash From Operating Activities 0.024 0.021 0.021 0.015 0.004
Non-Cash Items 1.777 1.891 1.139 0.659 0.4
Cash Interest Paid 0.002 0.002
Changes in Working Capital -0.461 1.195 0.387 -0.636 -0.044
Cash From Investing Activities -20.537 -16.134 -3.908 -0.05 -0.022
Capital Expenditures -0.022 -0.047 -0.002 -0.05 -0.022
Cash From Financing Activities 30.087 28.845 0.07 21.216 3.539
Issuance (Retirement) of Stock, Net 30.093 28.85 0.075 21.216 3.539
Foreign Exchange Effects
Net Change in Cash -2.702 3.526 -12.94 15.47 -0.383
Cash Taxes Paid 0.028 0.036 0.026
Other Investing Cash Flow Items, Total -20.515 -16.087 -3.906
Issuance (Retirement) of Debt, Net -0.006 -0.005 -0.005
Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
Net income/Starting Line -3.508 -13.592 -10.346 -6.896 -3.622
Cash From Operating Activities -3.888 -12.252 -9.448 -6.402 -4.313
Cash From Operating Activities 0.006 0.024 0.018 0.012 0.006
Non-Cash Items 0.443 1.777 1.354 1.023 0.551
Changes in Working Capital -0.829 -0.461 -0.474 -0.541 -1.248
Cash From Investing Activities 2.214 -20.537 -11.848 0.98 -0.009
Capital Expenditures 0 -0.022 -0.015 -0.013 -0.009
Other Investing Cash Flow Items, Total 2.214 -20.515 -11.833 0.993 0
Cash From Financing Activities -0.001 30.087 30.106 0.241 0.242
Issuance (Retirement) of Stock, Net 0 30.093 30.111 0.244 0.244
Issuance (Retirement) of Debt, Net -0.001 -0.006 -0.005 -0.003 -0.002
Net Change in Cash -1.675 -2.702 8.81 -5.181 -4.08
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
EQT Partners AB Private Equity 10.8 2855847 304827 2022-07-08 LOW
Trill AB,LLC. Corporation 9.6472 2551020 2551020 2021-09-28
Jacinto (Richard II) Individual Investor 9.4543 2500000 850947 2022-12-31 LOW
Lytton (Laurence W) Individual Investor 4.0539 1071970 -308296 2021-12-31 MED
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.961 782989 349 2022-12-31 LOW
Giuffre (Randall Michael) Individual Investor 1.4983 396184 35130 2023-01-03 LOW
Omega Advisors, Inc. Investment Advisor 1.1345 300000 100000 2021-12-31 LOW
Jacob Asset Management of New York, LLC Investment Advisor 0.8839 233730 -4770 2022-12-31 LOW
Pilnik (Richard D) Individual Investor 0.7937 209882 55555 2023-01-03 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.6991 184870 -349 2022-12-31 LOW
Lynch (Timothy Patrick) Individual Investor 0.3792 100259 -100000 2022-12-31 LOW
Burroughs (Amy Louise) Individual Investor 0.2772 73288 17156 2023-01-03 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.2723 72012 2814 2022-12-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.252 66629 0 2022-12-31 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.2496 65997 1067 2022-12-31 LOW
Pauls (Dietrich John) Individual Investor 0.211 55804 20000 2022-11-16
Morgan Stanley & Co. LLC Research Firm 0.1672 44201 2194 2022-12-31 MED
Alcorn Harry W Jr Individual Investor 0.1663 43981 399 2022-03-22 MED
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.1612 42634 0 2022-12-31 LOW
Citadel Advisors LLC Hedge Fund 0.1483 39216 4304 2022-12-31 HIGH

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group

500K+

Traders

92K+

Active clients monthly

$53M+

Monthly investing volume

$30M+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

DiaMedica Therapeutics Inc. Company profile

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company's lead product DM199 mimics the behavior of naturally occurring human KLK1 proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The Company also has other product pipelines for IgA Nephropathy and African Americans with CKD.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, DiaMedica Therapeutics Inc revenues was not reported. Net loss increased 11% to $13.6M. Higher net loss reflects General and administrative - Balancing increase of 23% to $3.8M (expense), Research and development - Balancing increase of 7% to $8.3M (expense), Governmental assistance research incen decrease from $205K (income) to $0K.

Industry: Bio Therapeutic Drugs

301 Carlson Parkway
Suite 210
MINNEAPOLIS
MINNESOTA 55305
US

Income Statement

  • Annual
  • Quarterly

News

A file photo shows a part of a stack of 500 Canadian gold coins, worth $1 million USD according to Sprott Money, is displayed at the precious metals dealer's booth at the Prospectors and Developers Association of Canada (PDAC) annual conference in Toronto

PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise

Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.

09:37, 31 March 2023
People use DBS automated teller machines (ATMs) in Singapore March 31, 2022.

Singapore's DBS has seen inflows in SVB aftermath, CEO says

DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.

09:24, 31 March 2023
Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., March 29, 2023.

US STOCKS-Futures muted as investors await key inflation data

U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.

09:16, 31 March 2023
A file photo of the logo of Australian energy company Origin pictured in Melbourne, Australia, July 3, 2016

Asia M&As drop to decade low as tumultuous backdrop deters dealmaking

Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.

09:14, 31 March 2023
A file photo of a worker shoveling coal in a supply truck at a yard on the outskirts of Ahmedabad, India, October 25, 2018.

Coal India surpasses annual output target for first time in 17 years

Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.

09:13, 31 March 2023
A file photo of bull and bear symbols in front of the German stock exchange in Frankfurt, Germany, February 12, 2019.

Global IPOs marred by banks and recession enjoy few bright spots

A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.

09:06, 31 March 2023
A file photo of Unicredit Bank logo seen in this illustration taken March 12, 2023.

UniCredit shareholders gather to vote on CEO's new pay scheme

Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.

09:04, 31 March 2023

People also watch

Natural Gas

2.20 Price
+3.540% 1D Chg, %
Long position overnight fee -0.4092%
Short position overnight fee 0.3873%
Overnight fee time 21:00 (UTC)
Spread 0.005

Gold

1,969.66 Price
-0.550% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0102%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

28,478.70 Price
+1.100% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

US100

13,186.80 Price
+1.680% 1D Chg, %
Long position overnight fee -0.0249%
Short position overnight fee 0.0027%
Overnight fee time 21:00 (UTC)
Spread 3.0

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading